Ohshima K, Shimizu K, Akimoto A, Tsuda T, Omawari N, Awata H
Department of Primate Research Institute, Kyoto University, Aichi, Japan.
Nihon Yakurigaku Zasshi. 1987 Sep;90(3):171-5. doi: 10.1254/fpj.90.171.
Effect of OU-1308 (17s, 20-dimethyl-6-oxo-prostaglandin E1 methyl ester) on uterine motility in anesthetized rats and monkeys was examined by means of the balloon catheter or open-end catheter method and compared with that of PGF2 alpha. OU-1308 and PGE2 alpha exhibited uterine contractile activity at the dose of 30 micrograms/kg, i.v., on day 8 of pregnancy and 10 micrograms/kg, i.v., on day 20 of pregnancy in rats. In monkeys on day 50 approximately 120 of pregnancy, both compounds enhanced uterine motility at 10 micrograms/kg, i.v. Intragastric administration of OU-1308 at 500 micrograms/kg, however, was without effect in monkeys. These results indicate that when administered intravenously, OU-1308 was as potent as PGF2 alpha in terms of uterine contractile activity in pregnant rats and monkeys.
采用球囊导管法或开口导管法研究了OU-1308(17s, 20-二甲基-6-氧代前列腺素E1甲酯)对麻醉大鼠和猴子宫运动的影响,并与PGF2α的作用进行了比较。在大鼠妊娠第8天静脉注射剂量为30微克/千克、妊娠第20天静脉注射剂量为10微克/千克时,OU-1308和PGE2α均表现出子宫收缩活性。在猴妊娠约50天第120天时,两种化合物静脉注射10微克/千克均能增强子宫运动。然而,在猴中胃内给予500微克/千克的OU-1308没有效果。这些结果表明,静脉注射时,在妊娠大鼠和猴中,就子宫收缩活性而言,OU-1308与PGF2α一样有效。